The CEO of Pantarhei, Herjan Coelingh Bennink, will be presenting at the BioCapital Europe Conference on March 15, 2017 in Amsterdam. An ideal opportunity to meet us and discuss possibilities to collaborate, partner with or invest in Pantarhei’s programmes.
On Friday March 17, 2017 Pantarhei will sponsor a symposium entitled “Estrogens for the treatment of breast cancer”. Lectures will be presented by Herjan Coelingh Bennink (Results of High Dose Estrogen (HDE) treatment of breast cancer), Richard Santen (Effect of estrogens in preclinical breast cancer models) and Andrea Genazzani (Breast cancer: molecular and hormonal basis of metastasis). The session will be chaired by Piero Sismondi.
The CSO of Pantarhei, Carole Verhoeven, will attend the St Gallen Breast Cancer Conference in Vienna. She will present a poster summarising the the design of the clinical study with estetrol in patients with advanced breast cancer (ABC E4 study). The hypothesis of this study is that the fetal estrogen estetrol may have anti-tumour effects in patients with advanced ER+ breast cancer and that it most likely will also improve patients quality of life by reducing symptoms of estrogen deficiency. This study will be conducted at three clinical sites in Germany. Enrolment is anticipated to start in April this year.
Pantarhei Oncology will be visiting the 32nd Annual EAU Congress in London. A poster presentation by Ellen Dutman, CRA at Pantarhei, on Saturday March 25th will show the results of a clinical study with the estrogen E4 in healthy men. The objective of the study was to investigate the efficacy and safety of estetrol for its potential use in the treatment of prostate cancer with special emphasis on the effect of estetrol on testosterone levels. The results suggest that E4 may be suitable for the treatment of advanced prostate cancer.